















Michael D. Gosky 
 












Submitted to the Graduate Faculty of the 
 
Graduate School of Public Health in partial fulfillment 
  
of the requirements for the degree of 
 















UNIVERSITY OF PITTSBURGH 
 















Michael D. Gosky 
 
 
It was defended on 
 
April 16, 2021 
 




Elizabeth M. Felter, DrPH, MCHES 
 Assistant Professor, Department of Behavioral and Community Health Sciences 
Graduate School of Public Health 
University of Pittsburgh 
 
Thesis Co-Advisor: Robin E. Grubs, M.S., PhD, 
 Associate Professor, Department of Human Genetics 
Graduate School of Public Health 
University of Pittsburgh 
 
Thesis Co-Advisor: Quasar S. Padiath, MBBS, PhD  
Associate Professor, Department of Human Genetics 
Graduate School of Public Health 


































Assessment and Development of Online Educational Materials for Autosomal Dominant 
Leukodystrophy 
 
Michael D. Gosky, M.S. 
 




Many individuals utilize online resources following a diagnosis to gain additional health 
information. Patients and caregivers alike in the rare disease community have shared their desire 
for more updated, patient-friendly online information. Autosomal Dominant Leukodystrophy 
(ADLD) is a rare, adult-onset demyelinating condition with symptoms typically presenting in the 
4th to 6th decade of life. There is currently a limited amount of online educational resources about 
ADLD, and the material available varies in content and its technical nature is difficult for most 
readers to understand. 
In this study online educational materials were assessed for readability and content. A 
survey was developed and shared with patients and caregivers to assess their experience in 
gathering information about ADLD from physicians, other healthcare professionals, and online. 
This survey also asked what information participants would like included in the development of 
educational materials. The survey was distributed through the ADLD Facebook page support 
group, and through an email list of individuals consented to be contacted for research purposes.  
All resources evaluated were written above an 11th grade level and contained variable 
information on ADLD. A total of 33 participants responded to the survey. Most participants used 
the internet to find information about ADLD following a diagnosis. In addition to online resources, 
patients and caregivers utilized other resources such as physicians, and genetic counselors to learn 
more about ADLD, though no source was identified as being the most beneficial. Participants also 
 v 
indicated that they would prefer a fact sheet to be developed by physician(s), genetic counselors, 
researchers, or other patients to provide information on management, risks, and current research. 
Based on survey responses, a fact sheet was developed. This study impacts public health 
as the development and use of updated, easily understood educational materials aids in 
patient and caregiver understanding, and may promote communication between patients, 
caregivers, and healthcare professionals. 
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1.0 Introduction 
When faced with a medical diagnosis, many people, including family members of the 
person with the diagnosis, turn to the internet for information. Approximately 1 out of every 3 
people diagnosed with a medical condition, or who have a family member diagnosed, turn to online 
educational materials to better understand the diagnosis.1 Additionally, there is an upward trend in 
individuals advocating for themselves to be a part of clinical trials and connecting with specialists.2 
This demonstrates that more individuals are turning to online educational materials, and desire to 
participate in research that may benefit themselves and others diagnosed with the same or similar 
conditions.  
The term “rare disease” is defined differently in various parts of the world. In the United 
States, it is defined as a condition that affects less than 200,000 individuals, corresponding to a 
prevalence of fewer than 7.5 out of every 10,000 people, while in Europe its defined as a condition 
that affects fewer than 5 out of every 10,000 individuals.3 There are over 6,800 different rare 
diseases diagnosed within the United States, and these conditions are estimated to affect between 
25 to 30 million individuals. Rare diseases include conditions with a wide spectrum of phenotypic 
effects such as cystic fibrosis, Huntington’s disease, and malignant mesothelioma.4 While these 
conditions may be caused by various genetic and/or environmental factors, they fall into the same 
category of “rare disease” as they affect less than 200,000 people in the United States. Some of 
these conditions, such as Huntington’s disease, have been described for decades, while others have 
been more recently identified. Although some conditions may have more extensive research due 
to earlier identification, collectively, there is a growing desire for informative, updated, accurate, 
and accessible information for individuals and families affected by rare diseases.5  
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Several rare diseases are considered to be neurodegenerative, or conditions characterized 
by the loss of neurons in the central or peripheral nervous system. This loss of neurons can lead to 
a variety of symptoms such as ataxia or dementia, with a wide age range of symptom onset, 
depending on the specific condition.6 Additionally, some rare conditions are classified as a 
“leukodystrophy,” which are conditions  caused by the loss of myelin surrounding neuronal axons.7 
One such rare condition is Autosomal Dominant Leukodystrophy (ADLD).  
ADLD is currently described in at least 24 families including over 70 individuals in the 
literature, though it is likely underdiagnosed.8 It is a progressive condition characterized by 
autonomic symptoms such as loss of bladder control, erectile dysfunction, and autonomic 
cardiovascular dysfunction that can initially appear similar to the symptoms experienced by 
individuals diagnosed with multiple sclerosis (MS). Symptoms tend to manifest between ages 40-
60, however, distinct changes on brain MRI can be identified 10 years prior to initial symptom 
onset.9–15 This condition is known to be caused by pathogenic variants in the LMNB1 gene located 
on chromosome 5q23.2.16 Although the genetic etiology of ADLD may be understood, there is 
still a great need for ongoing research in the condition.  
While the ADLD community is smaller than other rare disease communities, members still 
demonstrate commitment to be included in research and in the development of support groups and 
educational materials.17 Even though research on ADLD diagnosis, treatment, and prognosis is 
currently on going, there is a limited amount of patient-friendly online educational material 
available for individuals and families affected by ADLD. The material that is available tends to 
include technical language that may be difficult for the lay public to understand. This lack of 
accessible and understandable information is detrimental as many individuals, including patients 
and caregivers alike, turn to online sources for information about their diagnosis. Many of the 
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online resources available provide variable information about ADLD. Some sites include basic 
information about how the condition is inherited while others provide more detailed and scientific 
information. Some sites include links to support groups that are available for related conditions 
while other sites do not. There is variability in what each piece of educational material includes or 
does not include. Although utilizing a combination of these sources and research articles may 
provide some clarity to patients and/or caregivers, understanding current resources requires both 
advanced education and a high level of health literacy. 
The rationale for this study is derived from inspection of online educational materials for 
patients and family members affected by rare conditions. More specifically, there is a general lack 
of easily understandable information available online about ADLD including recurrence risk, 
genetic basis, features of the condition, and prognosis. This study, to our knowledge, is the first of 
its kind, as it assesses the current literature and available educational material, and directly surveys 
both patients and caregivers to assess the ease at which they can find information about ADLD 
online, what they would like included in online educational materials, and how they would prefer 
to receive this information.  
1.1 Specific Aim 1 
Evaluate existing patient educational resources to ascertain what information is available, 
determine if it is specific to ADLD, and assess the overall readability of the resource by calculating 
the reading level of the material. 
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1.2 Specific Aim 2 
Design and disseminate a formative assessment to inform the development of ADLD-
specific educational materials and develop culturally competent educational material for ADLD 
patients and their families. 
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2.0 Literature Review 
2.1 Background 
   Neurodegenerative diseases are a heterogenous group of conditions that result from 
progressive neuronal degeneration and/or death.  Currently, it is estimated that there are several 
hundred different neurodegenerative diseases.18 Neurodegenerative diseases include well studied 
conditions such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease 
(HD), and multiple sclerosis (MS) among others. In the case of AD, HD and PD, the primary 
problem is in the neuron itself, as opposed to MS which is a demyelinating disorder that eventually 
leads to cell death. While these conditions are clinically distinct, involving different types of 
neurons in different locations of the nervous system, they all share the same general feature—the 
condition is due to the dysfunction and ultimately death of neurons.18 
Some neurodegenerative diseases are known to have a single genetic etiology. For 
example, HD is caused by extra trinucleotide repeats of cytosine, adenosine, and guanine (CAG) 
in the HTT gene encoding the huntingtin protein.19 Other neurodegenerative conditions, such as 
MS, are thought to be caused by a combination of genetic and environmental factors. As conditions 
such as AD, HD, PD, and MS have been identified, diagnosed, and treated for decades, and as the 
public becomes more aware of them, numerous patient resources have become available.  
While there are neurodegenerative and demyelinating conditions that have been identified, 
and even have their genetic etiologies well documented, there is a lack of, and clear need for 
accessible, updated, and understandable educational materials for individuals with these conditions 
and their families. One such condition is Autosomal Dominant Leukodystrophy. 
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2.2 Autosomal Dominant Leukodystrophy 
Myelin is a lipid-rich substance synthesized and maintained in the central nervous system 
(CNS) by specialized cells known as oligodendrocytes. Regions that are enriched with myelinated 
axons are “whiter” or lighter in color than unmyelinated regions, which explains the name “white 
matter” (WM) as used in relation to the CNS. Myelin insulates neuronal axons and accelerate the 
transmission of electrical impulses.20 Autosomal Dominant Leukodystrophy (ADLD) is one of 
several fatal neurodegenerative conditions characterized by loss, abnormal deposition, 
maintenance, or disruption of the myelin sheaths surrounding the axons of neurons in the CNS, 
known as leukodystrophies.7 Some more common leukodystrophies include X-linked 
adrenoleukodystrophy, Canavan disease, and Krabbe disease. These conditions present with a 
wide variety of symptoms, from vision and hearing problems to difficulty moving and eating. 21 
In 1984, Eldridge et al. first identified and described ADLD in 10 men and 11 women 
which they called “hereditary adult-onset leukodystrophy simulating chronic progressive multiple 
sclerosis.”9 This kindred of individuals were all Irish-American, however individuals having 
different ethnicities, including Japanese, Irish, and Italian among many others, have been 
identified. 22–24 ADLD is not more common in any particular racial or ethnic group, and it is 
considered to be a rare condition. Currently there are at least 24 different families including over 
70 individuals affected with ADLD described in the literature, although ADLD is likely 
underdiagnosed. 8 
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2.2.1 Features of ADLD 
ADLD is a progressive, adult-onset, demyelinating condition with symptoms typically 
starting between ages 40-60. It is characterized by radiological findings and autonomic symptoms 
including autonomic cardiovascular dysfunction, often followed by pyramidal and cerebellar 
signs, ataxia, tremor, and pseudoexacerbations.9–13 This condition initially seems similar to 
multiple sclerosis, especially in relation to the combination of motor, autonomic and cerebellar 
problems experienced by the patient.9  However, ADLD presents with some difficult to identify 
but key differences, namely the early and extensive presentation of autonomic disturbances, and 
specific changes seen on magnetic resonance images (MRI).9,11,14,15 
Commonly, the first outwardly noticeable manifestations of ADLD are the autonomic 
symptoms, including bladder dysfunction, constipation, orthostatic hypotension, or erectile 
dysfunction.8 These symptoms are often the reason why individuals initially seek medical care. 
However, there are indications of ADLD that can be seen by MRI a decade prior to the onset of 
symptoms.10,25 These findings on T2-weighted images are typically extensive and symmetrical 
white matter hyperintensities seen from the frontal lobe to the cerebellum and involving the corpus 
collosum, posterior part of the internal capsule, and middle cerebellar peduncles. Additionally, the 
white matter around the ventricles seems to be less affected.10,11,26–31 Widespread demyelination 
occurring throughout the CNS  is also a feature of ADLD. More recent studies show that in addition 
to the radiological findings, there is a buildup of lactate in the cerebrospinal fluid (CSF) in the 
lateral ventricles of individuals diagnosed with ADLD.26  Less common features of ADLD  include 
a form of dementia, neurocognitive decline, REM sleep behavior disorder, and cardiovascular and 
skin noradrenergic failure.7,32–36  
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2.2.2 Genetic Etiology of ADLD 
ADLD is caused by alterations involving the LMNB1 gene located on chromosome 5q23.2, 
which encodes the lamin B1 protein.16 The typical role of lamin B1 is to act as a component of the 
nuclear lamina, which is a structure that helps to support the nuclear envelope in cells.37 The lamina 
plays an essential role in modulating the structure and mechanics of the nucleus, as well as aids in 
regulating gene expression through chromatin positioning and integrating cytoskeletal dynamics 
within the cell. These roles have numerous implications in cell proliferation, migration, senescence 
and aging.37,38 There is also evidence to suggest that lamin proteins, such as lamin B1, are used 
during DNA replication, including the initiation of DNA replication.39,40 In mouse studies, Lamin 
B1 is also necessary for the development of the dendrites of neurons.41 Other studies have shown 
that Lamin B1 is needed for normal organogenesis, brain development, and neuronal 
development.42 
The majority of individuals with ADLD are found to have a duplication of the LMNBI 
gene.16,43–45  However, there has been a report identifying an Italian family who have a large 
deletion of approximately 660 kilobases (kb) located 66kb upstream of an LMNB1 promoter. Due 
to this deletion, an enhancer region was adopted, which resulted in an increase in the total amount 
of lamin B1 expressed in cells beyond the expected level. Interestingly, individuals with this 
deletion showed either no or less autonomic dysfunction than patients who have the gene 
duplication.46 At least three additional families with upstream deletions have been identified. These 
individuals experienced earlier symptom onset, but no dysautonomia, and reduced brain stem and 
cerebellum involvement on MRI compared to individuals with a duplication. 47 
Exactly how these duplications, or deletion, lead to the development of ADLD is not yet 
entirely understood. Evidence has shown that this increased amount of lamin B1 produced in cells 
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can lead to different adverse effects such as nuclear rigidity, reduced axonal growth, dysregulation 
of genes involved in skeletal development, the immune system, and neuronal development, and 
the demyelination of axons.41,48–50 Several studies have shown that in mice with LMNB1 
overexpression, the increase in lamin B1 leads to lipid dysregulation. This is specifically harmful 
to the ability of oligodendrocytes to create and maintain the myelin sheaths, which in turn could 
cause ADLD.50–52 These mouse models provide valuable insight into the development and course 
of the disease, but it is important to recognize that the findings of research with animal models 
may not be entirely translatable to human patients. Other in vitro studies indicate the involvement 
of other cell types.11,29,44,46 
2.2.3 ADLD Diagnosis 
Commonly, people with ADLD do not show outward signs of being affected until their 
fourth or fifth decade of life, and in general, they live around two decades after these symptoms 
start to appear.9,10 As there is no cure, the main treatment for people with ADLD is the management 
of symptoms through palliative care.53 Often, one of the first challenges is to correctly diagnose 
ADLD since it is sometimes initially mistaken for chronic progressive multiple sclerosis.9,11  
The diagnosis of ADLD is made through clinical evaluation, MRI analysis, and genetic 
testing. This genetic analysis is often done through the use of an array CGH to detect deletions and 
duplications, through single-gene deletion/duplication analysis of the LMNB1 gene, or a multigene 
panel which includes deletion/duplication analysis of LMNB1.8 While there are no established 
diagnostic criteria, the presence of clinical features of ADLD, including MRI findings and genetic 
test results indicating LMNB1 involvement, would be consistent with a diagnosis of ADLD.  
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2.2.4 Psychosocial Concerns 
The accurate diagnosis of ADLD comes with many implications such as altered life 
expectations, and family planning. These potential changes should be kept in mind by healthcare 
professionals including geneticists, genetic counselors, and other providers when discussing topics 
such as risk, and testing options. 
In contrast to most other leukodystrophies which are typically inherited in an autosomal 
recessive or X-linked manner, ADLD is inherited in an autosomal dominant fashion.54 Therefore, 
both males and females can be affected, and an individual needs only one pathogenic variant of 
the LMNB1 gene to develop the condition. In addition, the children of an affected parent have a 
50% chance of inheriting the pathogenic LMNB1 variant and developing ADLD. ADLD is also an 
adult-onset, which is uncommon for leukodystrophies.12 
Most women and men in the United States and elsewhere have their first child before the 
age of 40.55–57 For people diagnosed with ADLD, this means that an individual with an ADLD 
pathogenic variant may not know they have the condition until after they have already had children. 
This brings up concern that an affected parent passed on the pathogenic variant of the LMNB1 
gene to their child(ren), and this parent may want to know the chances that their child did inherit 
the variant. Additionally, family members of individuals with ADLD may want to know their gene 
status for reproductive planning purposes. These are concerns that have been examined in the HD 
community. 
A European study compared individuals who were tested for HD and found that over 50% 
of people who tested positive already had children prior to the positive test result As a part of this 
study individuals were asked what motivated them to pursue testing, and the researchers identified 
three major reasons: individuals wanted to know their chances of passing on the expanded gene to 
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their children, individuals wanted to know their status because they did not want to have a child 
who has a parent affected by HD, and individuals wanted to know when they should plan on having 
children. This study also followed individuals after their initial testing for three years and found 
that 69% of the non-carriers had subsequent pregnancies while only 39% of HD carriers had 
subsequent pregnancies.58 While HD is more prevalent than ADLD, it is an autosomal dominant 
adult-onset condition similar to ADLD. Individuals with ADLD may also want to pursue testing 
for a number of reasons including family planning purposes. 
Another concern in the HD community regarding having children is the feeling of guilt. 
This guilt could stem from feeling like they passed on a pathogenic copy to a child and the child 
would eventually develop HD, feeling like the child will have to experience challenges associated 
with having an affected parent, or feeling regret that he/she did not adopt a child, instead of having 
a biological child, or pursue prenatal testing. Two qualitative studies examine the issue of knowing 
or not knowing risks of having HD and reproductive decision making. In these studies one of the 
themes that emerges is the feeling of guilt.59,60 Extrapolating to ADLD, it is possible that parents 
diagnosed with ADLD experience similar feelings of guilt because they had children without 
knowing that they had a pathogenic copy of a gene that their children could inherit. Genetic 
counselors could address this feeling of guilt to help facilitate adaptation and coping. 
Similarly, since a brain MRI can identify features suggestive of ADLD years prior to a 
diagnosis, individuals with ADLD may wish to share this information with at-risk relatives, and 
genetic counselors can assist in facilitating this discussion.8,10,25 Genetic counselors can also assist 
with DNA banking, or storing DNA for future use. As more research is done, it is possible that 
having this DNA stored could inform the individual or family members of additional risks and 
may promote increased screening or surveillance. 
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A desire to learn more information about ADLD is another concern individuals with the 
condition may have, but unfortunately there is a lack of educational materials available specifically 
about ADLD. While there is ongoing research in ADLD that is reported in peer-reviewed literature 
journal articles are not always easily understood by the public.  
Individuals diagnosed with ADLD could have a number of concerns when meeting with a 
genetic counselor. They may feel guilty for having children, are in denial about the diagnosis, are 
worried about other family members or what the future may hold or want to gather as much 
information about ADLD as possible. Genetic counselors are resources for both emotional support 
and for providing patient education. 
2.2.5 Commonalities and Differences Between ADLD and Other Diseases 
The symptoms a person with ADLD may experience are similar to a number of other 
neurodegenerative diseases. Multiple sclerosis is often one of the initial diagnosis individuals with 
ADLD receive due to the commonalities between the two conditions.9 Both ADLD and MS present 
in adulthood and have motor, cerebellar and autonomic disfunctions, and due to the higher 
incidence of MS, some with ADLD may be diagnosed with MS prior to genetic testing.8,9,61 The 
similarities continue into the basis of the neurodegeneration. Both ADLD and MS are progressive 
demyelinating conditions, and neuronal axons lose their insulating myelin and over time the 
neuron itself will die. Often people with MS will have periods of relapse and remission when the 
neurons in the central nervous system experience inflammation which damages the neurons, then 
partial or complete recovery from the damage may occur.61 
While MS and ADLD share some features, there are several notable differences between 
these two conditions. For example, on a brain MRI, individuals with ADLD have extensive and 
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symmetrical white matter hyperintensities that extends from the frontal lobe to the cerebellum and 
involves the corpus collosum, posterior part of the internal capsule, and middle cerebellar 
peduncles but the white matter around the ventricles seems to be less affected.10,11,26–29 A person 
with MS will show multifocal lesions around the spinal cord, cerebellum, brain stem, and 
periventricular area on MRI.8,15 These differences seen on MRI help distinguish whether an 
individual has MS or ADLD. Additionally, ADLD is caused by duplications or upstream deletion 
of the LMNB1 gene and follows an autosomal dominant inheritance pattern while there is no 
precise genetic etiology identified yet for MS, and it is thought to follow a more complex 
inheritance pattern. There have been studies that suggest a link between MS and the major 
histocompatibility complex located on chromosome 6p21.3, although pathogenic variants in one 
specific gene has not been found to be associated with MS15 
X-linked adrenoleukodystrophy (X-ALD) is another disorder similar to ADLD. X-ALD is 
caused by pathogenic variants in the ABCD1 gene located on the X chromosome.62 Around 95% 
of men with X-ALD inherited a pathogenic variant from their mother, while at least 4.1% of cases 
are de novo.63 X-ALD affects both the white matter in the nervous system and the adrenal cortex. 
There are three major phenotypes of X-ALD: childhood cerebral, adrenomyeloneuropathy (AMN), 
and Addison disease. Around 35% of individuals with X-ALD have the childhood cerebral 
phenotype, characterized by what initially looks like attention-deficit disorder, but progresses into 
impaired cognition, and behavioral, vision, hearing, and motor dysfunction. Typically, boys are 
diagnosed between four to eight years old and become totally disabled between 6 months to 2 
years after initial diagnosis. AMN affects about 40-45% of men with X-ALD. This typically 
presents between age twenty to fifty and is characterized by the progressive loss of muscle control 
including stiffness and weakness in the legs as well as loss of sphincter control. Between 40-45% 
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of men with AMN show signs of brain involvement on MRI, and in 10-20% of these men, the 
brain involvement is severe and leads to cognitive and behavioral disturbances.62 About 10% of 
men have Addison disease only which is characterized by adrenal insufficiency by age seven and 
a half, and commonly presents with unexplained vomiting and weakness. In about 70% of men 
with AMN and 90% of neurologically symptomatic boys, adrenal function is abnormal.62 The 
AMN phenotype closely resembles that of ADLD due to the age of onset, gait disturbances, loss 
of sphincter control, and sexual dysfunction that can be seen in both conditions.8,62 
While there are some similar features shared by ADLD and X-ALD, these two conditions 
result in distinct changes seen on MRI and have different genetic etiologies. X-ALD is inherited 
in an X-linked manner and in the majority of cases a male inherited a pathogenic variant from his 
mother. This also means that an affected male will have all carrier daughters but no affected sons 
unless his female partner is a carrier for the condition. It is also important to note that although X-
ALD is more often thought of as a condition only men are diagnosed with, there are cases where 
a female has inherited a maternal pathogenic ABCD1 variant and inherited a paternal Xq27-Ter 
deletion leading to a diagnosis of cerebral X-ALD.64 Additionally, over 20% of female carriers 
will develop spastic paraparesis and appear like they have AMN when they are middle-aged.62 
Lastly, only 40-45% of affected individuals with X-ALD will have clinical or radiologic brain 
involvement whereas in ADLD the symmetric white matter hyperintensities are a key feature in 
an individual with the condition.62 
Huntington’s disease (HD), another adult-onset neurodegenerative condition, shares some 
similar features to those of ADLD. HD is caused by having a  trinucleotide repeat expansion of 
cytosine, adenine, and guanine (CAG)  in the HTT gene.65,66 This repeat expansion eventually 
causes the loss of neurons in the putamen, caudate, cerebrum, substantia nigra and several other 
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brain regions..66,67 Due to this loss of neurons, individuals progressively start to lose motor control, 
and experience cognitive decline and personality changes.66 Similar to ADLD, HD is an adult onset 
condition with the average age of diagnosis being 45 years with an average age of death between 
54 to 55 years, and it is inherited in an autosomal dominant fashion.66,68,69 
However, in contrast to ADLD there is anticipation that occurs with the size of the CAG 
repeats in the HTT gene.66 Therefore, from one generation to the next the size of the repeat can 
expand, and this is correlated with an earlier age of symptom onset.70 Studies have shown that 
anticipation in HD is largely due to instability of the CAG repeat during spermatogenesis, so nearly 
all large expansions are inherited from an affected individual’s father.71 However, there have been 
reported cases of juvenile onset HD that have been found to be due to maternally inheriting an 
expansion.72 Another difference is that there have been reports of Alzheimer’s disease co-
occurring in patients with HD.73 This difference, while not insignificant, may simply be due to the 
fact that HD has been studied much longer than ADLD.  
There are a number of conditions that share features with ADLD. Although these conditions 
may clinically overlap with each other, it is clear that ADLD is a unique diagnosis. MS, X-ALD, 
and HD have been studied for decades and more research has been done on these conditions when 
compared to ADLD, and ADLD is a more recent discovery. There have been specific online sites 
created for MS, X-ALD, and HD that have created and maintained educational materials about 
these conditions. Additionally, there are a number of support groups available for individuals and 
families dealing with a diagnosis. Individuals affected by HD also have a number of national 
organizations such as the Huntington’s Disease Society of America and the European Huntington 
Disease Network that engage in research, educational, and advocacy efforts.74,75 These online sites 
and support groups can be a valuable resource for families. An online search for ADLD-specific 
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educational materials yields few results. Much of the available online information comes from the 
National Center for Biotechnology Information’s GeneReviews, the National Institutes of Health’s 
Genetic and Rare Diseases Information Center, and the Online Mendelian Inheritance in Man. 
There is a clear need for the creation of educational materials for individuals and families dealing 
with a diagnosis of ADLD. 
2.3 Current Resources 
At present, searching online for support groups or educational materials for individuals 
affected by neurodegenerative diseases yields over one billion of hits depending on which specific 
condition is being searched. However, in comparison, searching specifically for “ADLD support 
groups” yields just 16,400 hits, dramatically fewer when compared to other conditions such as 
HD, X-ALD, or MS.  
Similarly, there are significantly more websites created that contain educational material 
for these other conditions. ADLD is a rare condition, affecting far fewer individuals than MS, X-
ALD, or HD, yet there is a need for support groups and understandable educational materials. 
Often, one of the first things individuals with a new diagnosis do is to search for information about 
the diagnosis. While this can include speaking with healthcare professionals, people frequently 
turn to searching online and try to identify information from websites. Over 80% of Americans 
turn to the internet to find health information, including information about a specific disease, 
specific treatments, or alternate treatment options. Additionally, 20% of people look online to find 
out more about ongoing research and experimental treatments.76 Globally, this correlates to over 
70,000 health-related searches on Google each minute, or over 1 billion searches a day according 
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to Google’s Health Vice President Dr. David Feinberg.77 Therefore, it is crucial for websites aimed 
at patients and their families to use language that most people can understand.  
In the case of ADLD, much of the available information comes from scientific journal 
articles. These articles are intended for researchers, healthcare professionals, or generally use 
technical language, and the overall readability of these has gone down over time.78   
Understanding the literacy level of a target audience is a key component in the creation of 
educational materials. This is especially true when it comes to medical information. Currently, the 
average American reads at the 7th to 8th grade level.79–81 Both the American Medical Association 
(AMA) and National Institutes of Health (NIH) recommend that medical information intended for 
the public should be written at or below a 6th grade reading level.80,82,83 Additionally, the 
government in the United Kingdom suggests that authors should aim for a reading level of age 
9.80,84 Additionally, when it comes to online reading, people tend to only read about 18% of what 
is written on a page.85 Therefore it is also important that information be conveyed in a concise 
manner.  
2.3.1 Patient support/advocacy resources 
Having a diagnosis of ADLD is considerably more rare than having a diagnosis of MS, which 
affects 3.6:100,000 women and 2:100,000 men.86 Individuals with MS can be referred to several 
different support groups, including to online sites such as the National Multiple Sclerosis Society, 
MS World, and Patients Like Me, among many others.87–89 In comparison, while the exact 
incidence of ADLD is not yet known, the number of online support groups is limited. Presently, 
the only online site is a Facebook group available specifically for individuals or families affected 
by ADLD.90  
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While support groups specifically intended for those affected by ADLD are limited, other 
support groups are available. Some of these support groups include Hunter’s Hope, 
Leukodystrophy Australia, and the United Leukodystrophy Foundation.91–93 While these groups 
do provide information and support for individuals with leukodystrophies, they are not specifically 
geared toward ADLD. ADLD does share many commonalities with other leukodystrophies, 
however, individuals with ADLD face challenges that those with more common leukodystrophies 
do not.  
In general, support groups offer individuals and families affected by a condition many 
benefits such as reducing feelings of isolation or stigmitization. They can also help alleviate stress, 
provide a sense of empowerment, and can act as a resource to provide more information about 
treatments, or how a condition progresses over time.94 While studies have shown that in-person 
support groups lead individuals to be more open and honest, online support groups also offer 
opportunities for individuals to share their experiences. Additionally, online support groups have 
the benefit of providing more flexible schedules and can connect people who do not live near 
enough to attend in-person sessions.94,95 Online groups are particularly useful for individuals with 
a rare disorder as they can provide support in creating a “new normal” for patients and their 
families, act as a place where individuals can freely share their experiences, act as a source for 
crowdfunding new treatments, and provide information for new members, or those more recently 
diagnosed.96,97  
Additional support group opportunities could connect individuals affected by ADLD, care 
takers, healthcare providers, and researchers to provide information on the condition and provide 
a stronger sense of community. As demonstrated in an online webinar hosted by the United 
Leukodystrophy Foundation, this community is committed to finding out more information about 
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ADLD.17 While the development and implementation of an ADLD-specific support group may 
take months or longer to fully form, this community possesses a strong desire to learn as much as 
they can about ADLD, and one way to provide them with this information is by creating 
educational materials.17 
2.3.2 Educational Resources  
Since the identification of ADLD as a unique disease, there has been a significant amount 
of research that has been done to accurately define the condition. While this research provides 
clarity on manifestations and disease progression, these studies are published in scientific journals 
which tend to be written at a level most readers cannot understand.78 Often, after a new diagnosis, 
individuals will search for the condition online in order to further their understanding of what the 
diagnosis means for themselves, relatives, and friends.  
Much of the online information available to ADLD patients comes from the National 
Center for Biotechnology Information’s GeneReviews, the National Institutes of Health’s Genetic 
and Rare Diseases Information Center (GARD), the National Institutes of Health’s MedlinePlus 
and the Online Mendelian Inheritance in Man (OMIM).8,98–100 Additionally, searching for 
“Autosomal Dominant Leukodystrophy,” “ADLD symptoms,” or “Adult Onset Autosomal 
Dominant Leukodystrophy,” on the YouTube platform yields no results, limiting the amount of 
available information further. While GeneReviews, GARD, MedlinePlus and OMIM are reputable 
for providing accurate information, there is a clear need for additional online educational materials.  
All three of these resources offer a detailed overview of the condition. The GARD site is 
intended for people who have rare or genetic diseases as well as healthcare providers, researchers, 
advocacy groups, and members of the general public.101 This site utilizes Orphanet, a European 
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reference portal to create the disease summary, and the Human Phenotype Ontology database to 
create a summary of the condition and describe possible symptoms.102,103 While this site does 
provide a concise overview of ADLD, it does lack in areas such as providing additional resources 
or support groups. The support group noted on the GARD site is Alex the Leukodystrophy Charity, 
which provides support and information for genetic leukodystrophies, but is not focused solely on 
ADLD.99,104 
GeneReviews acts as a resource for clinicians, and provides comprehensive information 
for inherited conditions including diagnosis, management, and genetic counseling 
considerations.105 Thus, the target audience for this source is not individuals affected by a 
condition, rather for healthcare providers. While this site is more comprehensive than other sites, 
it is written in a journal format, which is not ideal for most readers.78  
The MedlinePlus site provides a thorough description of ADLD including many possible 
symptoms and the genetic basis for the condition. The goal of the site is to provide free, reliable, 
easy to understand, and advertisement-free information about many different conditions.100,106 
While this site may accomplish those goals, it does not provide any links to support groups, nor 
does it thoroughly describe how ADLD is inherited.  
The OMIM site provides detailed information about ADLD, including a description, 
clinical features, inheritance, diagnosis, gene mapping, molecular genetics, and cytogenetics. This 
site does not provide links to any support or advocacy groups. Additionally, it was last updated in 
2016.98 Since 2016, research has advanced understanding of ADLD, and therefore, this site is not 
the most up-to-date of the sources where individuals can find information about ADLD. Of note, 
the site directly states that while this information is available to the public, it is intended for 
physicians, researchers, and advanced students of science and medicine.107   
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Utilizing these sources along with other research articles may help provide an 
understanding of what to expect after a diagnosis of ADLD, however, the available sites could 
possibly be missing relevant information for individuals affected by ADLD and/or present 
information in a scientific manner that would not be understood by the lay public. Prior to the 
creation of educational materials it would be important to elicit the information needs of 
individuals affected by ADLD.17 
2.4 Creating Educational Materials 
The creation of well-designed and easily understandable educational materials can be a 
challenging task. There are a number of important factors to consider in the development of 
educational resources such as the type of information to include, the organization and format of 
the information, as well as the target audience.  
When developing medical-based educational materials, a key consideration is general 
literacy and health literacy. Studies have shown that the average American reads at the 7th to 8th 
grade level.79–81 Both the American Medical Association (AMA) and National Institutes of Health 
(NIH) recommend that medical information intended for public use should be written at or below 
a 6th grade reading level.80,82,83 While this is the current recommendation, not all authors follow 
this suggestion. This can lead to misunderstanding as readers may not completely comprehend 
what is written, and/or fail to make appropriate health decisions. 
Health literacy is tied to general literacy but is more specific to the ability of a person to 
comprehend basic medical information needed to make informed healthcare decisions.108 Over 
one-third of the population in the United States has “below basic” or “basic” health literacy skills, 
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meaning that they have “no more than the most simple literacy skills” or they have “the skills 
needed to perform simple literacy tasks.” These individuals do not show the ability to summarize 
information, make inferences from material, recognize relationships within text, or understand the 
purpose of less common tests.109,110 These are vital skills when attempting to comprehend medical 
information. 
One of the major initiatives by Healthy People 2030, a group organized by the U.S. 
Department of Health and Human Services in order to create and promote public health initiatives, 
is to increase the health literacy level in the United States.111  About half of the U.S. population 
has an “intermediate” literacy level, meaning that they have the ability to summarize information, 
make inferences from material, recognize relationships within text, or understand the purpose of 
less common tests, but do not have the skills necessary to read or understand lengthy texts, make 
complex inferences, or summarize information from complex works.109,110 Therefore, most 
individuals struggle with comprehending complex medical information including understanding a 
diagnosis, treatment options, or a provider’s medical plan. This, in turn, could mean that many 
individuals are not making informed medical decisions for themselves, rather relying on their 
provider to make choices for them. For example, one study on this topic found that over half of 
the individuals in the study preferred to let their physician have the final say in decisions related 
to their medical care.112 This indicates that some people would rather trust their physician to make 
their healthcare decisions, rather than relying on their own understanding, and this could lead to a 
physician making a decision for a patient that the patient would not have made for her/himself, 
which is not always negative, but is incompatible with the ethical concept of autonomy. 
An additional consideration when creating educational material is the importance of 
ascertaining the informational needs of the audience. There are numerous ways to come to 
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understand of the needs of the target audience. One could conduct a survey, review what has 
previously been done, and/or create a focus group, among other choices. When choosing how to 
gather information, the author has a several factors to consider such as ease, cost, and efficiency. 
In the case of creating educational materials for a rare disease community, it may be appropriate 
to directly survey the members, or create a focus group. Through these platforms, one could 
identify the current understanding of the condition, and ascertain the educational needs of the 
community. This direct understanding may lead to the development of more specific and 
applicable material and benefit the community more than generalized information. 
Lastly, the format of the material is another factor to consider when developing educational 
resources. Some individuals may prefer to receive this information in the form of a fact sheet, 
while others may prefer a video with a comment section. In general, individuals tend to understand 
written medical information better when clear and concise language is used, preferably alongside 
pictures or illustrations.113 While the overall goal of providing information is the same, not all 
individuals prefer the same type or style of material distribution.  
2.5 Summary  
Although ADLD is a rare disorder, it serves as an example for the increasing demand for 
updated, easily understandable, and accessible educational information for patients and caregivers 
in the rare disease community. As more people are diagnosed with rare conditions, and as more 
people turn to the internet for health information, it is important that these individuals have the 
resources necessary to understand a diagnosis and make informed medical decisions.  
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 Currently, there is limited information available online for individuals and family members 
affected by ADLD, and the information that is available is not written at an easily understood 
level.78 This lack of ADLD-specific information is striking when compared to other similar 
conditions including other neurodegenerative disorders and leukodystrophies.  
While exact information needs of the ADLD community have yet to be determined, 
comparisons between other rare disease communities and the ADLD community can be drawn for 
the purpose of creating educational material including anticipated concerns or topics to be 
addressed in the resource such as psychosocial concerns, features of the condition, and ongoing 
research.  
In general and within the rare disease community, there is a growing number of people 
advocating for their inclusion in ongoing research including clinical trials and longitudinal studies 
to benefit individuals diagnosed with the same or a similar condition in the future, and this trend 
is demonstrated within the ADLD community.2,17 The lack of updated, easily understandable, 
online information available to the ADLD community, combined with the increased patient desire 




In the United States, there are over 6,500 conditions classified as a “rare disease” meaning 
that the condition affects less than 200,000 individuals.3,4 These conditions are caused by a variety 
of genetic and/or environmental factors, and express a variety of phenotypic characteristics. Some 
rare diseases are considered to be “neurodegenerative” and ultimately leads to the death of neurons 
in the central and/or peripheral nervous system.18 Some neurodegenerative conditions are adult-
onset such as Huntington’s disease (HD), or Parkinson’s disease (PD). Whereas HD and PD are 
primarily due to problems that arise from within the neuron leading to cell death, other 
neurodegenerative diseases are leukodystrophies, or conditions caused by loss, abnormal 
deposition, maintenance, or disruption of the myelin sheaths surrounding the axons of neurons in 
the CNS.7,21 One adult onset leukodystrophy is Autosomal Dominant Leukodystrophy (ADLD). 
ADLD is an adult-onset, progressive neurodegenerative condition, with symptoms 
typically beginning in the 4th to 6th decade of life. It is currently described in 24 families, including 
over 70 individuals, but is likely underdiagnosed. Accurate diagnosis of ADLD is often difficult 
as the symptom presentation initially appears similar to that of multiple sclerosis (MS), however, 
through clinical evaluation and genetic testing, an individual experiencing symptoms may be 
identified as having a pathogenic variant involving the LMNB1 gene located on 5q23.2, and thus 
diagnosed with ADLD.8 Although it is a unique diagnosis, ADLD, like many other rare diseases, 
shares similarities with other conditions including MS, HD, and other leukodystrophies such as X-
linked adrenoleukodystrophy (X-ALD).  
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 Some of the first symptoms an individual with ADLD may experience are autonomic 
dysfunction including neurogenic bladder, constipation, orthostatic hypotension, erectile 
dysfunction and feeding difficulties. Additionally, individuals with ADLD often experience 
subsequent coinciding onset of pyramidal and cerebellar impairment leading to ataxia, spasticity, 
and/or tremor that is often more prominent in the lower extremidies.8 Additionally, there are 
reports indicating initial preservation or mild impairment of cognitive ability early on in the course 
of the disease, but as it progresses psychiatric conditions and dementia can occur as late 
manifestations.10,32 Additionally, individuals with ADLD may experience pseudoexacerbations, 
where symptoms of the condition are exacerbated by fever or infection, but return to baseline after 
recovery.10 
 Aside from the outwardly visible manifestations of ADLD, identifiable features of the 
condition can be seen on brain and spine MRI years prior to diagnosis. These characteristic 
findings include symmetric T2-weighted hyperintensities starting at the motor cortex, down to the 
medulla oblongata through the posterior limb of the internal capsule. Eventually, these changes 
extend to the frontoparietal and occipital lobes, and lastly the temporal lobe. Optic radiations and 
U-fibers are not involved, and the periventricular white matter is mildly affected or spared entirely. 
Atrophy of the brain stem and spinal cord are noted and often show homogenous T2-weighted 
hyperintensity, and cerebrum, cerebellum and corpus callosum atrophy occur over time.8,10,29–31 
These findings are important to note as many individuals undergo MRI for a variety of reasons 
and such findings may lead to a diagnosis.  
 Although the manifestations of ADLD are diverse, ADLD shares similarities with a 
number of conditions including MS, HD, and other leukodystrophies. For example, some of the 
symptoms experienced by individuals with MS are similar to what may be experienced by an 
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individual with ADLD, such as the combination of autonomic, motor, and cerebellar dysfunction.9 
Additionally, as HD is another adult-onset neurodegenerative condition, individuals in the ADLD 
community may experience similar features, or psychosocial challenges as those in the HD 
community. Individuals with X-ALD, particularly those with the adrenomyeloneuropathy (AMN) 
phenotype of X-ALD, and individuals with ADLD share many similar symptoms including erectile 
dysfunction and sphincter control abnormalities.8,62 However, as these conditions are more 
common and have been studied for a longer period of time than ADLD, patients, family members 
of an affected individual, and caregivers have more resources to turn to. These resources include 
national organizations, online patient-friendly material, and disease-specific support groups. Some 
of these sources help provide an understanding of a diagnosis, information on symptom 
management, and connections to other specialists or other support groups and organizations.  
 Individuals diagnosed with ADLD do not have the benefit of numerous resources.  Online 
support groups are nearly nonexistent, with the exception of one Facebook group. Many of the 
available online educational materials provide links to general leukodystrophy support groups, or 
none at all. Additionally, should a patient or caregiver desire more information about ADLD, they 
have limited sources available to them outside of academic or research articles which may be 
difficult to understand.  
 This study had two main aims. The first was to ascertain the readability and content of 
currently available online educational material for ADLD. This initial review and assessment 
prompted the second aim of the study, which was to design and disseminate a formative assessment 
through a survey to individuals in the ADLD community to assess their experience with finding 
information about ADLD from physicians, other healthcare workers, and online, and assess the 
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educational needs of the community. Ultimately, this study was developed in part to help provide 
culturally competent educational resources to this community.  
3.2 Methods 
This study was approved by the University of Pittsburgh Institutional Review Board 
(CR19100151-001) (Appendix D). The survey utilized in the study was approved as an exempt 
addition to the study (STUDY21020157) (Appendix D.1). 
3.2.1 ADLD Educational Material Selection 
To identify and assess publicly available educational materials for ADLD an online search 
for “Autosomal Dominant Leukodystrophy” was done in February of 2021. Websites identified in 
this study are largely intended for medical professionals but are also available to patients and 
caregivers. This search identified four major sources of available educational materials.  
This study assessed the National Center for Biotechnology Information’s MedlinePlus and 
GeneReviews, the National Institutes of Health Genetic and Rare Disease (GARD), the Orpha.net, 
and the Online Mendelian Inheritance in Man (OMIM) pages for Autosomal Dominant 
Leukodystrophy. Additionally, one support group was identified on Facebook, although 
assessment of this source was not performed. 
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3.2.2 Readability 
To assess the readability of these sources, an online readability calculator was used 
(https://readabilityformulas.com/free-readability-formula-tests.php). This site processes text 
through 7 different readability formulas and provides results including the Flesch Reading Ease 
score, Gunning Fog, Flesch-Kincaid Grade Level, The Coleman-Liau Index, The SMOG index, 
Automated Readability Index, and the Linsear Write Formula. Each of these formulas analyze 
different variables to determine the readability score. In this study, the Flesch Reading Ease score, 
the Flesch-Kincaid Grade Level, and Automated Readability Index were used. The Flesch Reading 
Ease score provides a score from 0-100 based on average sentence length and average number of 
syllables per word, and this score can be converted into a school grade reading level as reported 
by the Flesch-Kincaid Grade Level score. The Automated Readability Index provides a score 
based on the average number of letters per word and average number of words per sentence. As a 
part of this study, some material including tables, diagrams, headings and subheadings were 
removed, and this may affect the overall scores generated. 
3.2.3 Formative Assessment 
A formative assessment was conducted through use of a survey, which was constructed 
using the University of Pittsburgh licensed Qualtrics (Appendix C). Prior to and during survey 
construction, input was sought from a geneticist with expertise in ADLD, a genetic counselor, and 
a health communication expert. Prior to distribution, the survey was piloted by 7 genetic 
counseling students, two genetic counselors, and a geneticist with expertise in ADLD and 
modifications to the survey were made based on feedback. This survey was designed to assess 
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patient and caregivers’ experience with obtaining educational material from physicians, other 
healthcare providers, and online. It also asked participants what they would like to know about 
ADLD, and how they would prefer to receive this information. This survey was composed of a 
total of 25 questions consisting of multiple-choice questions, open-ended questions, a Likert Scale, 
and ranking. Skip logic was utilized so that individuals only answered questions relevant to their 
situation. Additionally, participants could freely skip questions.  
3.2.4 Participant Selection 
Individuals diagnosed with ADLD, as well as related and unrelated caregivers for those 
diagnosed with ADLD 18 years of age and older were eligible to take the survey. Individuals 
younger than 18, or not affected with ADLD nor a caregiver for someone with ADLD were 
excluded from the study. A link to this survey was posted on the ADLD support group Facebook 
group (Appendix B.2). Additionally, ADLD patients who had consented to being contacted for 
research purposes as a part of Dr. Quasar Padiath’s ongoing research were sent an email (Appendix 
B) with the survey introduction (Appendix A) and link to complete the survey. Participants had 1 
month to complete the survey between February 25th, 2021 and March 21st, 2021. A reminder 
email was sent out on March 11th, 2021 (Appendix B.1). 
3.2.5 Analysis 
All of the survey responses were self-reported and anonymous. Data from all surveys were 
analyzed including both partial and complete responses. Data were analyzed using Qualtrics and 
Microsoft Excel to generate tables and descriptive statistics such as count, mean, median, standard 
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deviation, range, and percentages. In order to perform a Kruskal-Wallis test, the perceived ability 
of each resource to provide ADLD information was separated by resource and entered into R, 
which then performed the statistical test. 
3.2.6 Material Creation  
Creation of educational material was based on survey responses. Ultimately, as a part of 
this project a factsheet was created (Appendix E) and will be distributed through the ADLD 
support group Facebook page. The creation of this fact sheet included information derived from 
survey responses, as well as general information such as features, management, and genetic basis 
of ADLD.  
3.3 Results 
3.3.1 Readability and Content Analysis 
Initial inspection of available online educational material for individuals diagnosed with 
ADLD revealed that the material is written at a level well above the recommended 6th grade level. 
Flesch Reading Ease scores ranged from 13-34.2, and Flesch-Kincaid Grade Levels ranged from 
12.6-16.4. Additionally, the Automated Readability Index of these sites ranged from 11.2 to 16 




Table 1. Readability Measures of Online Educational Material for ADLD 






GeneReviews 13.0 16.4 16.0 
OMIM 31.2 12.6 11.2 
Orpha.net 18.2 14.6 14.6 
MedlinePlus 33.8 13.6 14.1 
GARD 34.2 12.6 12.7 
 
AFlesch Reading Ease score is given as a number between 0-100. Scores ranging from 0-29 indicate that the 
material is very confusing, 30-49 is considered difficult to read, 50-59 is fairly difficult, 60-69 is standard, 
70-79 is fairly easy, 80-89 is easy, and 90-100 is very easy to read. 
 
BFlesch-Kincaid Grade Level is the conversion of the Flesch Reading Ease score into the grade level 
equivalent. The number in front of the decimal indicates the grade level, for example, a score of 12.5 
indicates that the average U.S. student in 12th grade or 1st year in college can read and understand the 
material. 
 
CAutomated Readability Index produces an approximate U.S. grade level needed to understand the 
material. Grade 1 corresponds to the reading level of an individual who is around 6 years old, while grade 
12 corresponds to a reading level of an individual who is 17 years old. 
 
  
In addition to readability, these sources were evaluated for the information included on the 
webpage (Table 2). This includes accurate description of symptoms an individual with ADLD may 
experience, as well as information on the genetic basis of ADLD that mentions both duplications 
of LMNB1 and upstream deletions. These pieces of content were identified on all five webpages 
with the exception of the MedlinePlus site which did not specifically mention the upstream 
deletions that may cause ADLD. Whether or not the source provided detailed information on the 
inheritance pattern of ADLD including risk to children and siblings of a proband was assessed, 
with only the GeneReviews page including that information. Lastly, only the GeneReviews and 
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GARD pages provide links to possible support resources, though neither specifically included the 
ADLD Facebook page. 
Table 2. Content Assessment of Online Educational Material for ADLD 










GeneReviews Yes Yes Yes Yes 
OMIM Yes Yes No No 
Orpha.net Yes Yes No No 
MedlinePlus Yes NoB No No 
GARDC Yes Yes No Yes 
 
AIn order to receive a ‘Yes’ in this column, the source had to mention autosomal dominant as the 
inheritance pattern and include risk to offspring and/or siblings of a proband. 
 
BWhile the MedlinePlus site does identify that duplications of LMNB1 can cause ADLD, it failed to 
mention possible upstream deletions leading to the development of the condition. 
 




A total of 33 participants started the survey. A response rate for this survey was not able to 
be calculated due to the fact that the total number of people who could access the survey is 
unknown. Calculating how many people saw the survey is not possible as people may have seen 
the Facebook post or email and shared it with family members not in the email list, nor in the 
Facebook group. Data from the 33 responses were analyzed. Approximately half of all respondents 
(16/33) were individuals diagnosed with ADLD, and nearly half were family members of an 
individual diagnosed with ADLD (16/33). One individual marked that they were not diagnosed 
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with ADLD but did not provide additional information. A majority of participants (12/23) were 
between ages 41-65, and 57% (13/23) of respondents were female. Additionally, most reported an 
Asian or Pacific Islander ethnic background (15/23). The highest level of education reported was 
a graduate or professional degree beyond an undergraduate degree, with 78% (18/23) reporting 
that they had an undergraduate degree or graduate or professional degree. Additionally, 78% 
(18/23) were married and 59% of respondents (13/22) had at least 1 biological child. Demographic 
information is reported in Table 3. 
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Table 3. Participant Demographics 




Yes 16 48.48% 
No 17 51.52% 
Age  
(n=23) 
18-40 10 43.48% 
41-65 12 53.17% 
66 or older 1 4.35% 
Gender 
(n=23) 
Male 10 43.48% 
Female 13 56.52% 
Race 
(n=23) 
Asian or Pacific Islander 15 65.22% 




Other 3 13.04% 
Education 
(n=23) 
Some High School 2 8.70% 
High School/GED 2 8.70% 
Some College 1 4.35% 
Undergraduate Degree 6 26.09% 






Table 3 (continued) 
Marital Status 
(n=23) 
Single 5 21.74% 
Married 18 78.26% 
Biological Children 
(n=22) 
Yes 13 59.09% 




1 5 38.46% 
2 3 23.08% 
3 3 23.08% 
4 2 15.38% 
 
3.3.3 Age of Diagnosis 
Participants who indicated that they were diagnosed with ADLD were asked at what age 
they were diagnosed. A majority of respondents (13/16) indicated that they were diagnosed 
between ages 41-65. The range of age at diagnosis for ADLD patients is provided in Table 4. 
Table 4. Age of ADLD Diagnosis - Patients 
 n (n=16) % 
Younger than age 40 2 12.50% 
Age 41-65 13 81.25% 
Age 66 or older 1 6.25% 
Similarly, participants who indicated that they were family members of an individual 
diagnosed with ADLD were asked the age at which their family member was diagnosed. A 
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majority of responses (15/16) indicated that their family member was diagnosed between ages 41-
65 (Table 5). 
Table 5. Age of ADLD Diagnosis - Family Member 
 n (n=16) % 
Younger than age 40 1 6.25% 
Age 41-65 15 93.75% 
Age 66 or older 0 0% 
 
3.3.4 Genetic Services 
Participants were asked if they or their family member had been seen by a geneticist. Just 
over half of respondents (16/30) indicated that they had, while the remainder did not. Additionally, 
when asked more specifically which healthcare professional they or their family member has seen, 
47% (9/19) of respondents indicated they had met with a geneticist, while only 16% (3/19) 
respondents indicated that they, or their family member, had met with a genetic counselor. Nearly 
two-thirds of respondents (18/29) indicated that they had not received any genetic testing. Table 6 
summarizes data regarding genetic professionals and genetic testing. 
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Table 6. Specialists Seen and Genetic Testing 
  n % 
Has Seen Geneticist 
(n=30) 
Yes 16 53.33% 
No 14 46.67% 
Specific Specialist 
Seen (n=19) 
Geneticist 9 47.37% 




Don’t know / Unsure 3 15.79% 
Received Genetic 
Testing (n=29)  
Yes 10 34.48% 
No 18 62.07% 
Don’t know / Unsure 1 3.45% 
 
3.3.5 Educational Material Sources and Timing 
Participants were asked what resources they used to find out about ADLD and were able 
to select multiple provided answers. The most popular source for information about ADLD were 
online resources (10/40). Additionally, 37.5% of respondents (15/40) indicated that they reached 
out to a geneticist or other physician for information. All participants who selected the “other” 
option included family members as their source of information. Table 7 describes the sources 
participants used to find out information about ADLD. 
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Table 7. Source for Information on ADLD 
Source n (n=40) % 
Geneticist 7 17.5% 
Other physician 8 20.0% 




Support group 4 10.0% 
Online resources 10 25.0% 
Other 5 12.5% 
 
Additionally, participants were asked to rank sources on a Likert scale from 1-5 (1=Not 
helpful at all, 2=Slightly helpful, 3=Somewhat helpful, 4=Very helpful, 5=Extremely helpful) 
regarding how helpful each source was in providing understandable information about ADLD. 
Table 8 shows the count, mean, standard deviation, and median scores. Figure 1 shows a box and 
whisker plot comparing the median scores of resources on their ability to provide information 
about ADLD. A Kruskal-Wallis test did not identify a significant difference in median across the 
source type (p=0.98). 
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Table 8. Rating of Participants' Perceptions of Sources Helpfulness in Providing Information on ADLD 




Geneticist 14 2.86 1.29 3 
Genetic counselor 9 2.67 1.00 3 
Other healthcare 
professional 
14 2.86 1.17 3 
Webinar 11 3.00 1.48 3 
In-person 
seminar 
6 2.50 1.76 2 
Online support 
group 
9 2.44 0.88 2 
In-person 
support group 
7 2.57 1.51 3 
Online fact sheet 9 2.78 1.30 3 
Scientific articles 14 3.07 1.07 3 





Figure 1. Box and Whisker Plot Comparing Median Scores of Resources 
 
3.3.6 Online Educational Sources 
Nearly 90% of respondents (23/26) indicated that they have looked for information about 
ADLD online. Nearly half of participants (12/26) indicated that they check online once or a few 
times a year for information about ADLD, while 38% of respondents (10/26) indicating that they 
check at least once a month. Nearly one-third (9/26) of respondents indicated that when they or 
their family member was first diagnosed with ADLD it took them over two hours to find an answer 
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to their question, or they have yet to find an answer. Table 9 describes participants’ experience 
with finding online information about ADLD. 
Table 9. Respondents' Ability to Locate Information About ADLD Online 
  n (n=26) % 
Looked for info 
online  
Yes 23 88.46% 
No 3 11.54% 
Frequency  Once or a few times a 
day 
0 0% 
Once or a few times a 
week 
1 3.85% 
Once or a few times a 
month 
9 34.62% 
Once or a few times a 
year 
12 46.15% 
Never 4 15.38% 
Length of time to 
find answer  
< 30 minutes 3 11.54% 
30 minutes to 1 hour 2 7.69% 
1 to 2 hours 2 7.69% 
2+ hours, or have yet 
to find answer 
9 34.62% 
N/A 10 38.46% 
 
Additionally, participants were asked which online source, if any, was most beneficial in 
providing information about ADLD. A majority of participants (12/22) indicated that none of the 
online resources included in the survey question were most beneficial. Participants could 
optionally write-in a resource, though none did. Table 10 shows which source was found to be 
most beneficial.  
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Table 10. Online Source Participants Identified as Most Beneficial 
Source n (n=22) % 
GeneReviews 1 4.55% 
OMIM 1 4.55% 
NIH’s Genetic Home 
ReferenceA 
5 22.73% 
Orpha.net 3 13.64% 
None 12 54.55% 
AAs of October 2020 The Genetic Home Reference has become MedlinePlus 
 
3.3.7 Material Development and Distribution 
Participants were asked to indicate what information they would most like included in a 
developed educational material. Approximately half of the respondents (42/82) indicated that they 
wanted to see information on management of ADLD, and current research on the condition in a 
newly developed educational material. Additionally, participants were able to specify anything 
else they wanted to be included in the created material, and answers noted timeline to therapies, 
stage of research for therapies, how to maintain quality of life, and availability of treatments or 
preventative measures for family members. Table 11 shows what respondents want to see in an 
online educational material. 
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Table 11. Information to Include in a Developed Educational Material 
Item/Concern n (n=82) % 
Risk to family members 13 15.85% 
Risk to future pregnancies 7 8.54% 
Features of the condition 15 18.29% 
Management of the 
condition 
23 28.05% 
Current research 19 23.17% 
Other 5 6.10% 
 
Participants were asked to rank formats of educational material on a 1-5 scale (1 being the 
best, 5 being the worst). As shown in Table 12, the majority of respondents ranked a fact sheet as 
the best way to receive information about ADLD.  


















Fact sheet 2.10 
(1.06) 
8 (38.10%) 6 (28.57%) 4 (19.05%) 3 (14.29%) 0 (0%) 
Infographic 2.43 
(0.85) 
3 (14.29%) 8 (38.10%) 8 (38.10%) 2 (9.52%) 0 (0%) 
Video 2.33 
(1.08) 





3 (14.29%)  4 (19.05%) 1 (4.76%) 11 
(52.38%) 
2 (9.52%) 
Other 4.9 (0.29) 0 (0%) 0 (0%) 0 (0%) 2 (9.52%) 19 
(90.48%) 
 
Participants were asked to designate their preferred source to create, develop, and share 
educational material with them. Most respondents (7/9) indicated that they would prefer a 
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physician to be involved. Additionally, responses included other patients, researchers, and genetic 
counselors as potential sources of this material. 
The readability of the developed fact sheet was calculated using an online readability 
calculator (https://readabilityformulas.com/free-readability-formula-tests.php). Table 13 shows 
the Flesch Reading Ease, Flesch-Kincaid Grade Level, and Automated Readability Index of the 
developed material (Appendix E). 
Table 13. Readability of the Developed Fact Sheet 








62.5 8.3 8.2 
 
3.4 Discussion 
ADLD is a leukodystrophy that exemplifies the need for updated patient-friendly resources 
for providers, patients, and caregivers within the rare disease community. Although the ADLD 
community is smaller than other rare disease communities, patients and caregivers have expressed 
a desire for updated and easily understandable educational material.17 This study was developed 
to ascertain currently available online educational material for ADLD, and to determine ADLD 
patient and caregiver experience with gathering information from physicians, other healthcare 
providers, and online. It also elicited participants’ educational needs, preferred source of 
information, and desired format of educational resource.  
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3.4.1 Assessment of ADLD Online Educational Resources 
In this study, online educational materials for ADLD were evaluated for readability and 
content. Readability scores were based on three measures, Flesch Reading Ease, Flesch-Kincaid 
Grade Leve, and Automated Readability Index. The Flesch Reading Ease score is the result of a 
formula that considers sentence length and syllable number of the material assessed, and indicates 
the ease at which an individual could read said material. Flesch-Kincaid grade level, and 
Automated Readability Index scores represent the grade level necessary to understand the material. 
The readability of educational material is an important factor to consider as the average American 
reads at the 7th-8th grade reading level.79–81 The American Medical Association and the National 
Institutes of Health both recommend that medical information intended for public use should be 
written at or below a 6th grade reading level.80,82,83 Although this recommendation has been made, 
many online sources are written well above an 8th grade reading level, and there has been a general 
decrease in readability of scientific articles.78 Online educational material for ADLD assessed in 
this study were given Flesch Reading Level, Flesch-Kincaid Grade Level, and Automated 
Readability Index scores. Flesch-Kincaid Grade Level and Automated Readability Index scores 
were above the 8th grade reading level indicating that the average American would have difficulty 
understanding the material. All of the sources evaluated in this study scored above a 12 for the 
Flesch-Kincaid Grade Level, and above an 11 for the Automated Readability Index indicating that 
an individual would need to have beyond an 11th grade reading level to understand the material. 
Of note, the GARD site utilizes information provided by Orpha.net which may have impacted the 
overall readability scores for the site. Readability scores are based on formulas that assess both 
sentence length, and number of syllables present, though the type of content included in the 
resources is not evaluated by these programs.  
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The content included in these sources was examined by reviewing each resource. All of the 
sources provided information about ADLD including an overview of possible symptoms, and 
genetic basis of the condition, though of note, only the MedlinePlus site did not specifically include 
that upstream deletions may cause ADLD. Additionally, only the GeneReviews page included 
detailed information about inheritance including possible risks to children and siblings of an 
affected individual. Also, only the GeneReviews and GARD pages provided links to support 
groups, though neither specifically included the ADLD Facebook page. A newly diagnosed 
individual or caregiver may have to go to several different resources to understand the diagnosis, 
but even then, each source included in this study requires a reading level beyond that of the average 
American.  
3.4.2 Survey Demographics 
About half of the respondents of this survey were individuals diagnosed with ADLD while 
the rest were family members of an individual diagnosed with ADLD. Most patients (81.25%) 
indicated that they were diagnosed between age 41-65, and most family members (93.75%) also 
indicated that their affected relative was diagnosed between ages 41-65. This is consistent with 
previous findings indicating that the average age of diagnosis ranges from age 40-60.8–10  
Interestingly, over half of respondents (52.17%) indicated that they have a graduate or 
professional degree, suggesting that they likely could read and understand the currently available 
online resources. Though over 20% (5/23) indicated that they had some college education or less, 
indicating that they may encounter difficulty with understanding the available educational 
materials. Although many respondents indicated that they have an undergraduate degree or higher, 
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it is not a guarantee that they can understand medical information even if it is written at a level 
that they “should” be able to because they may not have the numeracy or scientific literacy needed.  
Additionally, a majority of participants (78.26%) are married, and nearly 60% had at least 
1 biological child. The finding that many participants have a child is consistent with the fact that 
over 40% of participants (10/23) were between the ages of 18-40, and the average American has 
their first child before age 40.55–57 
3.4.3 Perceived Ability of Sources to Provide Information 
Over 80% of participants indicated that they or their family member has met with a 
geneticist, genetic counselor, or other healthcare professional. These specialists would likely be 
able to provide information about genetic conditions including ADLD. In addition to these 
resources, both patients and caregivers often use the internet to look for more information 
following a diagnosis.76 This is consistent with the current study as over 88% of participants 
indicated that they used online resources to learn more about ADLD. Participants were asked how 
frequently they searched for information about ADLD online, and how long it took them to find 
an answer to their question. Nearly 40% of participants indicated that when they or their family 
member was first diagnosed, they searched for information at least once a month, and over one-
third of participants indicated that it took them 2 or more hours, or they have yet to find an answer 
to their question. This finding may indicate that meeting in-person with a specialist or meeting 
with a support group could be more beneficial in individuals’ quest to gather relevant information 
about ADLD than using online resources. However, when asked to rank various in-person and 
online sources on their ability to provide information about ADLD, scores averaged between 
“slightly helpful” and just above “somewhat helpful” with scientific articles averaging the highest 
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score. A box and whisker plot demonstrates the spread of scores, and median score for each 
resource evaluated. A Kruskal-Wallis test was performed to compare the medians of each group 
and it was found that not one source had a statistically significant higher or lower median score 
(p=0.98). This may further indicate that participants did not significantly favor or disfavor one 
source. This test may be the most appropriate statistical test as it compares the median scores of 
resources from within the same population. 
Currently, there is limited online educational material for ADLD. As demonstrated in this 
study, patients and caregivers regularly check online resources for information about ADLD. 
Available information is primarily found in scientific journal articles which often contain technical 
information that can be difficult for a person to understand.78 Participants were asked which online 
resource, if any, was the most beneficial in terms of helping them answer their questions about 
ADLD. Options provided to participants included the GeneReviews page, the OMIM page, the 
Orpha.net page, the NIH’s Genetic’s Home Reference page, and an option to write in a response. 
A majority of responses (54.55%) indicated that none of the provided resources were most 
beneficial. The second most popular response was the NIH’s Genetic Home Reference page. Of 
note, since the development of the study survey, the NIH’s Genetic Home Reference page has been 
converted into the MedlinePlus page for ADLD. This survey question included the option to 
include a specific resource through a text entry box, though no participant selected that option. It 
is possible that participants felt like one source not included in the survey question was the best, 
but due to the fact that they would have to type it in, chose to not include it.  
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3.4.4 Informational Needs  
When developing educational materials, assessing the informational needs of the target 
audience is a crucial step. Assessing these needs provides guidance in what information should or 
should not be included in the educational material. It is also a way to help promote patient-centered 
care. Patient-centered care involves care that is respectful of and responsive to patient preferences, 
needs, and values.114,115 This includes active communication between patients and physicians, but 
also applies to the development of educational materials as educational material may promote the 
communication between patients and their providers. Studies have shown that patient-centered 
care improves health outcomes for patients and increases the efficiency of care.116 Therefore, 
promotion of communication between patients and their doctors and developing tools such as 
educational material to aid this communication is likely beneficial. In the current study, 
participants were asked to indicate what information they would most like included in a developed 
educational material. 28.05% (23/82) of respondents wanted information about management of the 
condition and 23.17% (19/82) wanted current research to be included. Nearly one-fourth (20/82) 
of participants indicated that they want risk to family members and future pregnancies included in 
a developed educational resource. This may indicate that participants are unclear about the 
inheritance pattern or the risks for relatives. It is also possible that participants want this 
information for family planning purposes. Nearly 60% of participants had at least 1 biological 
child, which may indicate additional psychosocial concerns such as fear of passing on the genetic 
variant, or fear of having a child that may witness a parent experience the symptoms of ADLD, 
that could be addressed in an educational material. Additional responses included that participants 
want to know if there are specific therapies currently available, what the timeline until a therapy 
is available may look like, and if there are preventative measures family members may take in 
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order to reduce the risk of having ADLD or symptom severity. Currently, there are no management 
guidelines available for individuals diagnosed with ADLD, nor are there any available clinical 
trials for therapy. Current treatment involves evaluation by numerous specialized physicians, and 
is based on presenting symptoms.8 Additionally, much of the ongoing research is attempting to 
further identify and classify possible disease manifestations, and the underlying basis for genetic 
alterations involving the LMNB1 gene. As genetic alterations involving the LMNB1 gene are 
inherited in an autosomal dominant manner, the risk to a future pregnancy of a proband is 50% 
regardless of gender, and the risk to siblings is dependent on the genetic status of the proband’s 
parents. If one of the proband’s parents is found to have ADLD, then the risk to the proband’s 
sibling is 50%. Once a familial variant is identified, preimplantation genetic diagnosis (PGD) or 
preimplantation genetic testing for familial mutations (PGT-M) may be considered for couples 
considering using in-vitro fertilization (IVF) to conceive a pregnancy.8 Including this information 
in a developed educational material may help to provide clarity for patients about genetic risk 
factors, and aid in family planning. It may also help foster communication between ADLD patients 
and their physicians regarding possible reproductive options. 
It is possible that participants want risk to future pregnancies or family members included 
in a developed educational material due to concerns of possibly passing on a pathogenic variant to 
a child. As seen in this study, many participants already had children, and may fear that their child 
inherited the ADLD pathogenic variant. This issue has been well studied in other adult-onset 
disease communities, including the Huntington’s disease community. These studies found that 
individuals in the Huntington’s disease community felt a sense of guilt after having a biological 
child even if they did not know their genetic status prior to conception of the child.59,60 
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Extrapolating to ADLD, it is possible that individuals feel a similar sense of guilt, and wish to 
know risks for their current and possible future children.  
3.4.5 Preferred Format of Educational Material 
Participants were asked to rank formats of educational material on a 1-5 scale, with 1 being 
the best format, and 5 being the worst format in terms of conveying information about ADLD. 
Based on the responses, a video was ranked as the second-best format, while an infographic was 
third. Interestingly, participants ranked a fact sheet as their preferred format for a developed 
educational material. This may, in part, be due to the fact that 78% of participants (18/23) hold an 
undergraduate degree or higher, and have higher literacy skills, promoting a desire for written text 
rather than visual material. Studies have shown that the use of illustrations tend to allow for better 
understanding of material when coupled with clear and concise language.113 Therefore, an 
infographic, or video may have been considered to be the best format, had this survey not assessed 
the preference of participants.   
Fact sheets tend to be clear and concise, highlighting important information in an 
understandable manner, while infographics use pictures with minimal text providing an overview 
of a topic. Infographics are a beneficial way to communicate ideas particularly to individuals with 
lower health literacy, since they use visuals rather than extensive text. However, they may not 
provide as much detailed information as a fact sheet.113,117,118 Additionally, videos are also a format 
that may aid in patient understanding. The Patient Education Video Program found that 86% of 
individuals surveyed after watching a video about their care felt that the video helped them 
understand their treatment plan, medical condition, and overall health.119 Therefore, a multimedia 
approach may also be beneficial to aid in ADLD patient and caregiver understanding. An 
 53 
additional consideration may be in the development of additional online, and/or in-person support 
groups for individuals and families affected by ADLD. Studies have found that support groups are 
beneficial for individuals in the rare disease community.96,97 Individuals in the ADLD community 
have one online disease-specific support group available to them. Therefore, the creation of 
additional support groups may benefit the community as support groups often decrease the feelings 
of isolation and stigmatization. They may also provide a sense of empowerment and provide 
additional resources among other benefits.94–97 
3.4.6 Preferred Source of Information 
Participants were asked to designate their preferred source of information in the 
development of an educational material. Nine participants wrote in responses. A majority of 
responses indicated that participants desire a geneticist or physician to be the primary source of 
information. Additionally, responses included other patients, researchers, and genetic counselors 
as possible sources of this material.  
Physicians have extensive training in diagnosing and treating medical conditions. 
Similarly, geneticists diagnose and treat medical conditions related to an underlying genetic 
cause.120,121 Therefore, both of these sources offer a unique perspective in the development of 
educational material as they are well-versed in possible symptoms an individual may experience, 
current treatments available, and are often up-to-date on the research into many different 
conditions. Researchers often have diverse educational backgrounds, and should they focus on a 
particular disease such as ADLD, may provide specific information on the basis of that disease, 
symptoms a person may experience, and efficacy of treatments. These experiences also give them 
a unique perspective in the development of educational materials. Genetic counselors have 
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advanced training in both genetics and counseling, and often provide information and support to 
individuals diagnosed with genetic conditions.122 Genetic counselors regularly have to identify, 
and evaluate educational material prior to providing it as a resource to patients or caregivers, and 
often have experience in creating educational materials.123 Therefore, a combined approach by a 
team of physicians, researchers, and genetic counselors may be an ideal source for the development 
of educational materials. 
3.4.7 Considerations for Development of Educational Material 
The development of accessible, patient-friendly material is often a difficult task 
considering the low general literacy and health literacy of the lay public. The difficulty of 
conveying important ideas while writing below a 6th grade reading level may be exacerbated 
because key concepts related to diagnosis, genetics, inheritance, treatments, and surveillance may 
require terms that are considered to be above an 8th grade reading level. A number of studies have 
found that often online educational material is identified to be written above the NIH and AMA’s 
recommendation, though this may be due to the polysyllabic nature of necessary medical 
information.124,125 In order to convey information in an understandable manner, one should 
consider which topics require more advanced education and which can be written at or below a 6th 
grade reading level. Additional consideration might be given to developing additional educational 
material that can explain advanced or complex topics in an understandable manner. Studies have 
found that the inclusion of figures or visual aids tend to assist in patient understanding, especially 
when conveying risk information and would likely be beneficial in developed resources intended 
for the ADLD community, or other rare disease community.126  
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The fact sheet developed as a part of this study was found to have a Flesch Reading Ease 
score of 62.5 which is considered to be a “standard” or “average” score. It was also found to have 
a Flesch-Kincaid Grade level of 8.3 and an Automated Readability Index of 8.2 indicating that the 
developed material is written at the NIH and AMA’s recommended reading level as individuals 
with an 8th grade reading level could likely read and understand the fact sheet. 
3.4.8 Limitations 
There are several limitations that can be identified for this study. Data collected from the 
readability calculator is the result of a calculation based on sentence length and number of syllables 
within the source and does not assess content of the inputted material. The polysyllabic nature of 
the technical language necessary to convey ideas in the evaluated educational resources may have 
caused the readability scores to be elevated.  
All survey responses were self-reported. Participants’ had to recall how long they spent 
searching for online information, and how frequently they did this search, after they were first 
diagnosed, which may have been several years from the time they completed the survey. This 
could lead to inaccurate data if the participant could not precisely recall how frequently they 
searched for information or how long the searches took them. Additionally, years ago information 
was more limited in its availability which could have caused participants to spend longer times 
searching than they currently do.  
A further limitation of this study is that the ADLD Facebook page was not analyzed for 
readability or content. While this source is not directly intended to act as a primary source for 
information on ADLD, it does act as a place where patients, caregivers, and researchers interact. 
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Evaluation of this source would be difficult to do as individuals regularly post about experiences, 
and not all posts are directly providing educational information about ADLD. 
Selection bias is also a possible limitation of this study as the survey was posted online to 
the ADLD Facebook group but was not posted on all sites that individuals affected by ADLD visit. 
Individuals may have been motivated or deterred from participating based on the source they used 
to come across this survey, whether through email or online. The results may have been different 
if other sites were utilized for participant recruitment. 
Another limitation is volunteer bias as the survey was voluntary and only individuals 
motivated to participate did so. It is possible that individuals who initially took longer to locate 
educational materials online were more motivated to participate in this study than individuals who 
did not have this experience. 
A Kruskal-Wallis test was performed in this study to compare the median scores of 
resources’ perceived abilities in providing information on ADLD. This test is non-parametric and 
does not require that data follow a normal distribution. This test is often used to compare groups 
from within the same population as the observations within a group are not independent. This test 
also had a p-value of 0.98. This is likely due to the low count observed in the study as median 
values may change with additional observations. It is possible that combining groups into different 
categories and then comparing medians may yield different results, though this was not performed. 
It is also possible that performing a more limited assessment of only 4 resources may provide more 
responses and participant engagement. Additionally, a more expanded assessment, such as having 
7 possible Likert scale values may identify significant differences between resources, though 
participants may be overwhelmed with options if there are too many resources to evaluate. 
Alternatively, a different statistical test may yield different results. 
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While the exact response rate could not be determined, it is possible that individuals did 
not participate due to a number of factors including having difficulty accessing the survey, personal 
feelings toward providing information, lack of time to participate, or challenges in reading the 
survey. It is critical for researchers to recognize barriers that may prevent individuals from 
participating in research and to develop strategies to enhance recruitment. 
3.4.9 Future Research 
In the future, focus groups or qualitative interviews could be pursued to better determine 
participants’ use, opinions, and understanding of available online educational materials. In these 
settings, participants could more thoroughly describe the information they would like included in 
the development of educational materials, and they could evaluate the readability of available 
online educational materials. This input could inform investigators about the use of other tools or 
platforms where they could present information, such as through webinars, lectures, or interactive 
learning. Qualitative interviews and focus groups could also assess the ease at which a participant 
can locate online educational material.  
The analysis did not examine patients and family members separately when assessing the 
preferred format of educational material, preferred information to be included in a developed 
material, or preferred source of information on the developed material.  This type of analysis may 
be considered in future research as it is possible that patients and family members have different 
preferences and therefore, educational material could be tailored to meet the preferences of these 
two groups.  
Future research could include the development and piloting of additional educational 
materials, as well as having various stakeholders such as physicians, patients, caregivers, and 
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researchers evaluate the material for accuracy, readability, and ease of access. An additional 
resource that could be considered is the creation of an educational video as it was ranked as the 
second-best format for providing ADLD information in this study. Additionally, this study may 
serve as an example for assessing the educational needs of individuals in other rare disease 
communities and developing material for these communities.  
3.5 Conclusion 
This study found that online educational material for ADLD was limited in availability, 
difficult to read and understand, and includes variable content.  
The assessment of readability found that all of the studied online educational materials 
were written at a grade level well above the current recommendation of below a 6th to 8th grade 
level. Additionally, the evaluated resources provided different content about ADLD with some 
providing information about the genetic basis of the disease, inheritance and/or risks to 
pregnancies or siblings, while others did not.  
Participants indicated that they had tried to utilize resources outside of the internet for more 
information about ADLD, though no resource was identified as being the most helpful in finding 
information about ADLD.  
Additionally, this study found that participants desire a fact sheet to be developed that 
would provide information about management, risks, and current research. Participants also 
indicated that they would prefer this information to come from physician(s), researchers, genetic 
counselors, or other patients.  
 59 
In the development of patient-friendly educational resources, the following steps are 
recommended: 
• Material should be written at or below a 6th-8th grade level. 
• Clear and concise language throughout the material should be used, and the inclusion 
of pictures and visuals to aid explanations is encouraged. 
• The material should meet the educational needs of the target population. 
• The material should be piloted with various stakeholders including patients, family 
members, caregivers, and physicians. 
• Stakeholders should evaluate developed material. 
• The material should be shared on an accessible platform. 
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4.0 Significance to Genetic Counseling and Public Health 
4.1 Genetic Counseling 
Genetic counselors are heath care professionals with specialized training in genetics and 
counseling and act as a resource for individuals with a suspected or confirmed genetic diagnosis. 
Provision of genetic information is part of the genetic counselor’s role and this may include 
offering additional online educational materials to patients. This often puts genetic counselors in 
a unique position as they review the material for accuracy, readability, and relevance. Moreover, 
genetic counselors often have experience developing patient-facing educational materials.123 
Genetic counselors may interact with individuals in various rare-disease communities, and 
encounter situations where they are unable to provide educational materials or information on 
specific support groups, which are highly beneficial.96,97 Therefore, they may have first-hand 
experience in recognizing a lack of available resources for an individual or community, and be 
able to assist in the development of additional resources. 
 Numerous online resources provide information about genetic conditions, though not every 
resource uses understandable language. Genetic counselors should be aware of the current NIH 
and AMA reading level recommendations when assessing what resource might be best to share 
with their patients. Additionally, research into genetic conditions is growing, and as our 
understanding of genetics evolves, it is crucial to evaluate information, even from reputable 
sources, that may be provided to a patient for readability, accuracy, and relevance.  
 This study demonstrates that individuals in the ADLD community often search for 
information about ADLD online, with varying levels of success in getting answers to their 
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questions. Genetic counselors are uniquely positioned to help address the concerns of individuals 
diagnosed with, or are suspected of having, a genetic condition and are often involved in the 
creation of educational materials to benefit these individuals. It is important that genetic counselors 
are aware of literacy, and health literacy concerns of the lay public during the development of 
educational material.  
Participants of this study also indicated that they want current research included in a 
developed educational resource. This demonstrates the desire for updated information. As the field 
of genetics rapidly evolves, and our understanding of rare diseases progresses, genetic counselors 
should be aware that many sources may be considered out-of-date by the time they are reviewing 
them. 
This study also found that many participants have biological children. Since ADLD is a 
genetic condition, parents may be concerned regarding the risk for their child(ren) to be affected. 
Developed educational material should address the risk for family members and possible future 
pregnancies. Additionally, when relevant, educational material should include information on 
preimplantation genetic diagnosis, and prenatal testing. This information may help foster 
communication between patients, family members and healthcare providers, including genetic 
counselors, which in turn may enhance patient understanding. 
4.2 Public Health 
 
Public health efforts often address challenges that may affect many people in a given 
population, and public health initiatives are typically developed to try to prevent people from 
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experiencing these challenges.127 Therefore, issues pertaining to rare diseases are not often thought 
about as traditional public health concerns.128 That said, there are over 6,800 rare diseases that 
affect an estimated 25 to 30 million people in the United States alone, and there is compelling 
evidence to suggest that public health initiatives addressing concerns of individuals in the rare 
disease community may be beneficial.4,128 
One of the essential core functions of public health is to inform, educate, and empower.127 
This means that individuals working to improve public health should help inform and educate 
others. This is particularly important when addressing rare diseases as the knowledge and 
understanding of the condition can change rapidly.  
One challenge to providing education is the low level of literacy and health literacy in the 
general public. The average American reads at or below a 7th-8th grade level, and over one-third of 
the lay public has below basic, or basic health literacy skills, meaning that they do not have the 
skills to interpret complex information, or make inferences about material that could pertain to 
their health.109,110 These skills are crucial to understanding educational material, especially when 
the material is addressing a medical condition. To address this public health issue, Healthy People 
2030 promotes a public health initiative attempting to raise the health literacy of the public.111 
When developing educational material, it is important to recognize that the material may be 
accessed by individuals with low general and health literacy skills. 
This study found that many participants held an undergraduate degree or higher, indicating 
that they may have higher general literacy and health literacy skills. However, writing educational 
material about ADLD at or above the collegiate level would be a disservice as many people who 
may come across the information would not be able to read or understand it. Additionally, this 
study demonstrates the need for educational materials to be clear and concise as many individuals 
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indicated that none of the available online resources were most beneficial in aiding their 
understanding of ADLD. This may be due to the fact that the answer to their question was not 
included in any of the resources, or potentially it was, but the material was too dense or confusing 
for the reader to find the answer. As most individuals only read about 18% of what is written on a 
page, developed educational materials should be concise in order to facilitate understanding.85 
Other public health initiatives, such as the creation of disease-specific support groups, may 
benefit individuals in the rare disease community. This may help promote aspects of public health, 
though both the “inform, educate and empower” and “mobilize community/partnerships” core 
functions. Support groups are often beneficial for individuals facing a diagnosis of any medical 
condition, but are particularly beneficial for members of the rare disease community.96,97 Support 
groups allow for connections to be made between patients, family members, and providers, and 
often lessen the feeling of isolation and stigmatization, and encourage open communication and 
may provide a sense of empowerment.94–97 This is true for both in-person and online support 
groups.95,96 Online support groups offer the benefit of connecting people who do not live nearby 
each other, and allow for more flexible schedules, which may be seen as a benefit over in-person 
support groups. As individuals in the ADLD community currently do not have access to any 
ADLD-specific online support groups outside of the ADLD Facebook group, they would likely 
benefit from an additional opportunities to share their experiences and connect with other 
individuals/families and providers/researchers.  
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Appendix A Survey Introduction 
ADLD educational materials survey - Introduction 
 
We are inviting you to take part in a survey that is trying to determine the need for educational 
materials for individuals and families affected by Autosomal Dominant Leukodystrophy (ADLD). 
Ultimately, this research will help in the creation of educational resources for individuals and 
families affected by ADLD caused by alterations to Lamin B1 (LMNB1).  
 
We are surveying individuals diagnosed with ADLD, their family members, and unrelated 
caregivers and asking them to complete a brief (10 to 15 minute) survey. If you are willing to 
participate, this survey will ask about your experience with getting information about ADLD from 
doctors, other healthcare workers, and online. It will also ask about what you would like to learn 
about ADLD, and how you would prefer to receive this information. 
 
There are minimal risks associated with completing this survey including, but not limited to the 
infrequent breach of confidentiality. You will not receive any form of compensation for 
completing this survey.  
 
This survey is anonymous, so your responses will not be identifiable. All responses are confidential 
and electronically secured. Your participation is voluntary. You may skip questions, or stop the 
survey at any time, though any responses up to the point of exiting will be kept. If you choose to 
withdraw from this study, all data collected prior to withdrawal will be used. 
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You can reach out to the study Principal Investigator, Dr. Quasar Padiath (qpadiath@pitt.edu) if 
you have any questions. Thank you for considering participating and we appreciate your help in 
providing information that will be important in the creation of educational materials for individual 
and families affected by ADLD. 
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Appendix B ADLD Survey Email  
Dear Friends 
We are carrying out a survey to assess the need for educational materials for individuals 
and families affected by ADLD  (details attached).  
The survey is anonymous, very brief (~ 10 minutes) and is for ADLD patients, caregivers 
and family members. It is one survey per person. 
The same information has also been posted to the ADLD Facebook page. 
Please fill out the survey using the link below or in the attached file. Ultimately, this 
research will help in the creation of educational resources critical for the ADLD community.  
So, I encourage you to participate and also let others know about the survey. Do not hesitate 
to contact me for any further information. 
Best 
Dr. Quasar Padiath 
  







Appendix B.1 ADLD Survey Reminder Email 
Dear Friends 
I am following up on my previous email (below) to remind everyone about the Survey on 
Educational materials for ADLD (details attached). 
I wanted to thank everyone who has filled out the survey so far. Sixteen participants have 
filled out the survey and we would really like to have between 25-30 responses to be able to draw 
any meaningful conclusions. 
I would encourage any of you who have not filled it to do so and also encourage other 
ADLD family members/caregivers and patients to fill out survey . Please also forward the link to 
anyone who think might be interested.  The survey will be closed for response submission after 
March 19th, 2021 so that we can start analyzing the data. 
The link to the survey is below. 
Link to survey 
https://pitt.co1.qualtrics.com/jfe/form/SV_9mGpJ4kp0wDYyTb  
I hope that everyone is keeping safe. 
Thank you and Best Regards 
Quasar 
Appendix B.2  ADLD Facebook Group Post 
“Patients, family members and caregivers: Please take 10-15 minutes to read about and 
complete the following *anonymous* survey for Dr. Padiath's ADLD research team at UPITT. 
Direct link to the survey: https://pitt.co1.qualtrics.com/jfe/form/SV_9mGpJ4kp0wDYyTb” 
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Appendix C ADLD Survey 
ADLD Survey 1 
 
Q1 Have you been diagnosed with Autosomal Dominant Leukodystrophy (ADLD) due to 




Q2 Are you a family member of someone diagnosed with ADLD due to mutations or alterations 




Q3 Are you a caregiver (related or unrelated) for someone diagnosed with ADLD due to 




Q4 At what age were you diagnosed with ADLD? 
o Younger than age 40 
o Age 40-65 
o Age 66 or older 
 
Q5 At what age was the person you care for, or family member, diagnosed with ADLD? 
 
o Younger than age 40 
o Age 40-65 
o Age 66 or older 
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Q7 What kind of genetics professional have you or your family member seen? Please check all 
that apply. 
• Geneticist (doctor who specializes in genetic medicine) 
• Genetic counselor 
• Other medical professional 
• Don’t know / Not sure 
 
Q8 Have you gotten genetic testing? 
o Yes, I have gotten genetic testing 
o No, I have not gotten genetic testing 
o I don’t know, or am unsure if I have gotten genetic testing 
 
Q9 People get information about ADLD from many different sources. Where did you go to get 
answers for your questions and to look for information about ADLD? Please check all that apply. 
• Geneticist  
• Other physician 
• Genetic counselor 
• Other healthcare professional 
• Patient navigator 
• Support group 
• Online resources 
• Other (please specify) 
• _______ 
 




Q11 How often do you look for information about ADLD online? 
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o Once or a few times a day 
o Once or a few times a week 
o Once or a few times a month 
o Once or a few times a year 
o Never 
 
Q12 Thinking back to when you, or your family member, were first diagnosed with ADLD, how 
long did it take you to find an answer to your question about ADLD online? 
o Less than 30 minutes 
o 30 minutes to 1 hour 
o 1 to 2 hours 
o 2+ hours, or I have yet to find an answer to my question 
o N/A 
 
Q13 For the following items, please indicate how helpful they were in providing understandable 
information about ADLD (including possible symptoms, inheritance, finding additional 
resources, etc…). 






Very helpful Extremely 
helpful 
N/A 
Geneticist o  o  o  o  o  o  
Genetic 
counselor 




o  o  o  o  o  o  
Webinar o  o  o  o  o  o  
In-person 
seminar 
o  o  o  o  o  o  
Online support 
group 




o  o  o  o  o  o  
Online fact 
sheet 
o  o  o  o  o  o  
Scientific 
Articles 
o  o  o  o  o  o  
Other (please 
specify) 
o  o  o  o  o  o  
 
Q14 What online resource, if any, did you find most beneficial to answering your questions 
about ADLD? 
o GeneReviews 
o Online Mendelian Inheritance in Man (OMIM) 
o National Institutes of Health (NIH)’s Genetic Home Reference 
o Orpha.net 




Q15 Please tell us what specific information you would like to find in an online educational 
resource with regard to ADLD. Please check all that apply. 
• Risk to family members 
• Risk to future pregnancies 
• Features of the condition 
• Management of the condition 
• Current research 
• Other (please specify) 
• __________ 
 
Q16 What would be the most helpful ways to deliver information about ADLD to you? Please 
check all that apply. 
• Fact sheet (a 1 to 2 page document that describes ADLD) 
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• Infographic (a 1 page document that is made up of pictures with some text that explains 
ADLD)   
• Video from a genetics specialist 
• Comment section (Area where people could ask questions and a specialist could respond)   
• Other (please specify) 
• __________ 
 
Q17 Please rank the following formats in terms of most helpful to least helpful in conveying 
information about ADLD to you. A 1 would be most helpful and a 5 would be least helpful. 
These are the same items from the previous question. (Click and drag your selection up or down 
to place in your specified order). 
 ______Fact sheet 
 ______Infographic 
 ______Video from a genetics specialist 
 ______Comment section 
 ______Other (specified in previous question) 
 
Q18 If you could choose where you want this information to come from, what source would that 
be? This could be doctors/genetic counselors, other patients, other caregivers, etc… 




Q19 What is your age? 
o 18-40 years old 
o 41 to 65 years old 
o 66 or older 
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o Prefer not to answer 
 
Q21 What race and ethnicity do you identify as? (Please choose all that apply) 
• Black or African American 
• Asian or Pacific Islander 
• White/Caucasian 
• Native American or Native Alaskan 
• Hispanic, Latino, or Spanish origin 
• Middle Eastern or North African 
• Other 
• Prefer not to answer 
 
Q22 What is the highest level of education or highest degree you have received? 
 
o Some high school 
o High school or GED 
o Some college 
o Undergraduate degree (Associate’s or Bachelor’s degree) 
o Some graduate school 
o Graduate or professional degree (Masters’s, MD, PhD, etc…) 
o Prefer not to answer 
 






o Prefer not to answer 
 
Q24 Do you have any biological children? 
o Yes 
o No 
o Prefer not to answer 
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o 5 or more 
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Approved 
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• Padiath-consent-child-editable-no footer.pdf, Category: Consent Form;
 
As the Principal Investigator, you are responsible for the conduct of the research and to ensure accurate 
documentation, protocol compliance, reporting of possibly study-related adverse events and 
unanticipated problems involving risk to participants or others. The HRPO Reportable Events policy, 
Chapter 17, is available at http://www.hrpo.pitt.edu/.
Continuing review (CR) can be submitted by clicking “Create Modification/CR” from the active study at 
least 5 weeks prior to the expiration date.  
Clinical research being conducted in an UPMC facility cannot begin until fiscal approval is received from 
the UPMC Office of Sponsored Programs and Research Support (OSPARS). 
If you have any questions, please contact the University of Pittsburgh IRB Coordinator, Larry Ivanco.
Please take a moment to complete our Satisfaction Survey as we appreciate your feedback.
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Appendix E ADLD Fact Sheet 
 
What is Autosomal Dominant Leukodystrophy? 
 
Autosomal Dominant Leukodystrophy (ADLD) is an adult-onset condition caused by harmful 
changes to the LMNB1 gene, which provides instructions for the Lamin B1 protein. 
 
What is myelin and how does ADLD affect it? 
  
ADLD causes changes in myelin. Myelin is a substance made by special cells called 
“oligodendrocytes” in the central nervous system (CNS) which is the brain and spinal cord. 
  
Myelin is used to coat the axons of neurons in the CNS, and acts as an insulator, which speeds 
up the communication from one neuron to the next. 
  
If a person has damage to the myelin, and the body can’t fix it, then a person might experience 
health problems. 
  
ADLD is a “demyelinating” condition, meaning that people with ADLD lose the myelin coating 
on their neurons over time. 
 
What is a neuron? 
  
A neuron, or nerve cell, is a type of cell found in the nervous system. Neurons help us sense the 
outside world through our senses of touch, smell, sight, taste, and hearing. Neurons also tell 
our bodies how to move. Neurons do this by acting like electrical wires in the body. Like 
electrical wires, they use electrical signals to send messages from one neuron to the next. 
Myelin is like the insulating coating on electrical wires, helping to make sure that the signal 






What are the symptoms of ADLD? 
  
Often the first symptoms a person with ADLD might experience are a lack of bladder control, 
difficulty with bowel movements (constipation), men may have difficulty getting an erection 
(erectile dysfunction), and low blood pressure due to position of the body (orthostatic 
hypotension). 
  
These symptoms are often followed by impaired balance or coordination (ataxia), and shaking 
when moving (intention tremor). Emotional, behavioral, and memory problems may also be a 
later sign of ADLD. 
  
Specific changes to the brain and spinal cord can also be seen in individuals with ADLD, many 
years before they experience other symptoms. 
 
What is the treatment for ADLD? 
  
Currently, there is no specific cure or treatment available for people with ADLD. Treatment is 
based on the symptoms a person is experiencing and is focused on managing symptoms. This 
may involve a number of specialized doctors. 
 
What is the cause of ADLD? 
  
Our body is made up of many cells, and in the cells, there is DNA, which is the genetic 
information that is passed from parent to child. Specific parts of this DNA are called “genes.” 
Genes are the segments of DNA that act as an instruction manual for the body to make 
substances called “proteins.” Proteins have many different important jobs including helping our 
body to grow and work properly. The Lamin B1 protein has many different jobs and is thought 




We typically have two copies of our genes, one inherited from our mother, and one from our 
father. 
  
ADLD is caused by harmful changes involving the LMNB1 gene. This change is often an extra 
copy (duplication) of this gene, but sometimes, a missing piece of DNA (deletion) in front of the 
LMNB1 gene. These changes cause extra Lamin B1 protein to be made, and too much of this 
protein is thought to interfere with how oligodendrocytes work. 
 
How is ADLD inherited? 
  
ADLD is passed through families in an “Autosomal Dominant” manner. This means that both 
men and women can have changes to the LMNB1 gene. This also means that having a change 
such as a duplication or deletion in just one of the copies of the gene is enough for a person to 
experience symptoms and be diagnosed with ADLD. 
 
As seen in the picture below, when one parent has ADLD, there is a 50% chance with every 
pregnancy that the child will inherit the changed or altered LMNB1 gene, regardless of whether 
the child is a male or female. This also means that there is a 50% chance that the child will not 
inherit the altered gene. When a person has ADLD and received the changed LMNB1 gene from 




   
What current research is taking place? 
  
Much of the current research is trying to understand what exactly causes a duplication or 
deletion to happen in the LMNB1 gene. Additionally, animal models, which are non-human 
animals, such as a mouse, have been developed to mimic certain aspects of ADLD, and 
hopefully will help find possible treatments or a cure for ADLD. Medical advances happen every 
day, but no one knows how long it may take to find a cure for ADLD. 
 
Are there any clinical trials for ADLD? 
  
Clinical trials are experiments to see if a new treatment like a drug, or medical device, is safe 
and helps to treat people. Currently, there are no available clinical trials for people diagnosed 
with ADLD. This may change in the future, and www.clinicaltrials.gov offers an updated list of 












This resource is the ADLD Facebook support group. This site helps connect patients, family 
members, caregivers, and researchers, and allows for people to share their thoughts and 
experiences. It is specifically intended for people who have ADLD, have a family member with 




Axon – The part of the neuron that sends an electrical signal. 
 
Axon terminal – The end of the axon. This part is close to the dendrites of other neurons, so that 
they can receive the signal. 
 
Central Nervous System – The brain and spinal cord. 
 
Deletion – A missing piece of DNA. 
 
Dendrite – The part of a neuron that receives signals from the axon terminal of another neuron. 
 
DNA – The genetic information that is passed on from parent to child.  
 
Duplication – An extra copy of DNA. 
 
Gene – Part of DNA that provides instructions on how to make substances called proteins. 
 
Myelin – A substance that surrounds the axons of neurons. Myelin helps the signal move quickly 
from one neuron to the next and prevents the signal from accidentally going to unintended 
neurons. 
 
Neuron – A cell found in the nervous system that helps us sense the outside world and help tell 
muscles how to move. 
 
Nucleus – The control center of the cell. This is also where DNA is found. 
 
Oligodendrocyte – Specialized cells that make and maintain the myelin that coats axons in the 
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